PMID- 11596019
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 92
IP  - 8
DP  - 2001 Oct 15
TI  - Preoperative serum interleukin-18 level as a postoperative prognostic marker in 
      patients with gastric carcinoma.
PG  - 2050-5
AB  - BACKGROUND: Interleukin-18 (IL-18), a recently described cytokine produced mainly 
      by macrophages, stimulates interferon-gamma (IFN-gamma) production by natural 
      killer cells and T cells. Although it has been reported that serum IL-18 levels 
      are higher in patients with advanced tuberculosis and acute graft-versus-host 
      disease compared with normal controls, the authors found no reports regarding 
      serum IL-18 levels in patients with malignant solid tumors. The purpose of this 
      study was to determine serum IL-18 levels and their clinical significance in 
      patients with gastric carcinoma. METHODS: Peripheral blood samples were obtained 
      from 94 patients with gastric carcinoma who underwent curative surgery and from 
      50 healthy volunteers. The serum IL-18 level, the IFN-gamma, level, and the 
      Helicobacter pylori (HP) serology status were determined in each sample with an 
      enzyme-linked immunosorbent assay. RESULTS: The mean serum IL-18 level for all 
      patients was significantly higher compared with the mean level in healthy 
      volunteers (P < 0.01). IFN-gamma titers were below the level of detection in all 
      samples tested. When the patients were subdivided into groups, it was found that 
      the serum IL-18 level in patients with Stage II and III disease was significantly 
      higher compared with the level found in healthy volunteers (P < 0.01). The serum 
      IL-18 level decreased after patients underwent surgical resection. However, there 
      was no significant difference in the serum IL-18 level between healthy controls 
      and patients with Stage I or IV disease. Patients with IL-18 levels >or= 310 
      pg/mL (i.e., equal to or greater than the mean levels +/- 1 standard deviation in 
      the healthy volunteers) experienced a significantly lower survival rate compared 
      with patients who had IL-18 levels < 310 pg/mL after undergoing surgery (P < 
      0.05) despite a lack of any discernible difference in clinicopathologic factors 
      between the two groups. The serum IL-18 level was identified as an independent 
      postoperative prognostic factor in multivariate survival analysis using a Cox 
      proportional hazards model (hazard ratio, 4.89; P = 0.01). There was no 
      significant correlation between HP serology status and serum IL-18 levels. 
      CONCLUSIONS: The preoperative serum IL-18 level may represent a significant 
      postoperative prognostic determinant in patients with gastric carcinoma. Its 
      function in the host immune system remains to be elucidated.
CI  - Copyright 2001 American Cancer Society.
FAU - Kawabata, T
AU  - Kawabata T
AD  - Department of Surgery I, National Defense Medical College, Tokorozawa, Japan. 
      srg1717@gr.ndmc.ac.jp
FAU - Ichikura, T
AU  - Ichikura T
FAU - Majima, T
AU  - Majima T
FAU - Seki, S
AU  - Seki S
FAU - Chochi, K
AU  - Chochi K
FAU - Takayama, E
AU  - Takayama E
FAU - Hiraide, H
AU  - Hiraide H
FAU - Mochizuki, H
AU  - Mochizuki H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-18)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Aged
MH  - Antibodies, Bacterial/blood
MH  - Biomarkers/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gastrectomy
MH  - Helicobacter pylori/immunology
MH  - Humans
MH  - Interferon-gamma/blood
MH  - Interleukin-18/*blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Stomach Neoplasms/*blood/pathology/surgery
MH  - Survival Analysis
EDAT- 2001/10/12 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/12 10:00
PHST- 2001/10/12 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/12 10:00 [entrez]
AID - 10.1002/1097-0142(20011015)92:8<2050::AID-CNCR1544>3.0.CO;2-5 [pii]
AID - 10.1002/1097-0142(20011015)92:8<2050::aid-cncr1544>3.0.co;2-5 [doi]
PST - ppublish
SO  - Cancer. 2001 Oct 15;92(8):2050-5. doi: 
      10.1002/1097-0142(20011015)92:8<2050::aid-cncr1544>3.0.co;2-5.